Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 12Neoplasms 5Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sezary Syndrome 2Rectal Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × MK 2206 × Clear all
NCT01425879 2016-06-17

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
8 enrolled 8 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled 6 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡